New drug combo offers hope for bladder cancer patients who Can't take chemo

NCT ID NCT06263153

First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 20 times

Summary

This study tests whether combining futibatinib and durvalumab before bladder removal surgery can help patients with muscle-invasive bladder cancer who cannot receive standard cisplatin chemotherapy. About 24 adults with a specific genetic marker (FGFR overexpression) will receive the drug combination before surgery. The goal is to see if this approach can eliminate all cancer cells in the bladder by the time of surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic Taussig Cancer Center

    RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Michigan Comprehensive Cancer Center

    WITHDRAWN

    Ann Arbor, Michigan, 48109, United States

Conditions

Explore the condition pages connected to this study.